The U.S. Food and Drug Administration (FDA) issued a warning letter to Inova Genomics Laboratory (Inova) of Falls Church, Virginia, for illegally marketing certain genetic tests that have not been reviewed by the FDA for safety and effectiveness. The tests claim to predict patients’ responses to specific medications based on genetic variants. Selecting or changing drug treatment in response to the test results could lead to potentially serious health consequences for patients. The FDA is unaware of any data establishing that Inova’s tests can help patients or health care providers make appropriate treatment decisions for the listed drugs. The action reflects the agency’s commitment to monitor the pharmacogenetic test landscape and take action when appropriate to address a significant public health risk.
The use of some drugs can be informed by pharmacogenetic testing. When the agency has reviewed scientific evidence demonstrating a relationship between the drug’s effects and genetic variants and determined the information is sufficient to be included in the drug labeling, information about how to use the genetic test results to manage medication treatment is described in the labeling for the specific drug to assure safe use of the drug.
The FDA issued a warning letter to Inova for marketing pharmacogenetic tests that have not been reviewed by the FDA and that claim to predict patients’ clinical responses to specific named drugs, including antidepressants, opioids, cancer treatments, anesthesia and diabetes medications. The FDA has not reviewed and is unaware of any data establishing that Inova’s tests can help patients or health care providers use the listed drugs more safely or effectively. The warning letter requests that Inova respond, within 15 working days from the date the warning letter was received, with details of how the violations noted in the warning letter will be corrected. Any violations not corrected could lead to enforcement action such as seizure, injunction or civil money penalties.
Tests that make claims that have not been evaluated by the FDA may influence healthcare providers and patients to inappropriately select or change drug treatment based on the results from genetic tests. Acting on these results could lead to potentially serious health consequences for patients.
Last year, the agency issued a safety communication warning consumers and health care professionals about pharmacogenetic tests being marketed directly to consumers or offered through health care providers that claim to predict how a patient will respond to specific medications.
Following issuance of the safety communication, the FDA reached out to several firms marketing pharmacogenetic tests with claims to predict how a person will respond to specific medications in cases where the relationship between genetic (DNA) variations and the medication's effects has not been established. Most firms addressed the FDA’s concerns by removing specific medication names from their labeling, including promotional material and patient test reports.
